Jessica K Dyson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/829552/publications.pdf

Version: 2024-02-01

394421 315739 2,138 37 19 38 citations g-index h-index papers 38 38 38 3501 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	7.3	16
2	Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma. Digestive Diseases and Sciences, 2022, , .	2.3	3
3	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	3.7	33
4	Managing cognitive symptoms and fatigue in cholestatic liver disease. Expert Review of Gastroenterology and Hepatology, 2021, 15, 235-241.	3.0	13
5	Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. JHEP Reports, 2021, 3, 100202.	4.9	22
6	Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management?. Gastroenterology, 2021, 160, 649-651.	1.3	3
7	Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma. Hepatology, 2020, 71, 2164-2166.	7. 3	11
8	Review article: experimental therapies in autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2020, 52, 1134-1149.	3.7	12
9	UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice. Journal of Hepatology, 2020, 73, 499-501.	3.7	2
10	Pregnancy outcomes in women with liver transplants: systematic review and meta-analysis. Hpb, 2020, 22, 1102-1111.	0.3	19
11	Review article: unanswered clinical and research questions in autoimmune hepatitisâ€conclusions of the International Autoimmune Hepatitis Group Research Workshop. Alimentary Pharmacology and Therapeutics, 2019, 49, 528-536.	3.7	33
12	Paediatric to adult liver transition services: the state of play in the UK. Clinical Medicine, 2019, 19, 425-426.	1.9	12
13	Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. Hepatology Communications, 2018, 2, 421-436.	4.3	31
14	The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology, 2018, 68, 1487-1497.	7.3	48
15	Primary sclerosing cholangitis. Lancet, The, 2018, 391, 2547-2559.	13.7	276
16	Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet, The, 2018, 391, 1097-1107.	13.7	140
17	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Alimentary Pharmacology and Therapeutics, 2018, 48, 951-960.	3.7	34
18	Adult parenteral nutrition in the North of England: a region-wide audit. BMJ Open, 2017, 7, e012663.	1.9	16

#	Article	IF	CITATIONS
19	New metrics for the Lancet Standing Commission on Liver Disease in the UK. Lancet, The, 2017, 389, 2053-2080.	13.7	33
20	Fatal gastrointestinal histoplasmosis 15 years after orthotopic liver transplantation. World Journal of Gastroenterology, 2017, 23, 7807-7812.	3.3	12
21	Early Molecular Stratification of High-risk Primary Biliary Cholangitis. EBioMedicine, 2016, 14, 65-73.	6.1	17
22	Reply to $\hat{a} \in \infty$ Liver failure in human immunodeficiency virus $\hat{a} \in \text{``Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy \hat{a} \in \text{`Journal of Hepatology, 2016, 64, 753-754.}$	3.7	4
23	Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24â€h. Frontline Gastroenterology, 2016, 7, 16-23.	1.8	36
24	Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinics in Liver Disease, 2016, 20, 131-142.	2.1	16
25	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. Journal of Hepatology, 2016, 64, 234-238.	3.7	85
26	Implementation of the Lancet Standing Commission on Liver Disease in the UK. Lancet, The, 2015, 386, 2098-2111.	13.7	76
27	Fatigue in primary sclerosing cholangitis is associated with sympathetic overâ€activity and increased cardiac output. Liver International, 2015, 35, 1633-1641.	3.9	27
28	Novel therapeutic targets in primary biliary cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 147-158.	17.8	110
29	Unmet clinical need in autoimmune liver diseases. Journal of Hepatology, 2015, 62, 208-218.	3.7	56
30	Hepatitis B in pregnancy. Frontline Gastroenterology, 2014, 5, 111-117.	1.8	14
31	Prior hysterectomy and discomfort during colonoscopy: a retrospective cohort analysis. Endoscopy, 2014, 46, 493-498.	1.8	11
32	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterology, 2014, 5, 211-218.	1.8	254
33	Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. Clinical Medicine, 2014, 14, 551-555.	1.9	6
34	Diagnosis and management of patients with primary biliary cirrhosis. Clinical Liver Disease, 2014, 3, 52-55.	2.1	8
35	The New Epidemiology of Primary Biliary Cirrhosis. Seminars in Liver Disease, 2014, 34, 318-328.	3.6	66
36	Treatment of Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2014, 32, 597-604.	1.9	39

#	Article	lF	CITATIONS
37	Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. Journal of Hepatology, 2014, 60, 110-117.	3.7	487